Clinical Trials Browser

Phase 3 × Interventional × Myeloid × Clear all

NCT00843882 2026-04-13

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Phase 3 Active not recruiting

247 enrolled 19 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 3 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01366612 2026-04-03

FLUBUTBI

Phase 3 Terminated

53 enrolled 11 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06351631 2026-04-02

MK-3543-017

Phase 3 Recruiting

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT03401060 2026-03-31

DenosuMast

Phase 3 Completed

Osteoporosis, Mastocytosis, Systemic

NCT06093672 2026-03-25

GIV-IN-PV

Phase 3 Recruiting

Polycythemia Vera

NCT07489755 2026-03-24

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Phase 3 Not yet recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04472598 2026-03-23

TRANSFORM-1

Phase 3 Completed

252 enrolled 17 charts

Neoplasms, Primary Myelofibrosis

NCT05198960 2026-03-20

AVAJAK

Phase 3 Recruiting

Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3 Completed

199 enrolled 13 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06499285 2026-03-11

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Phase 3 Recruiting

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

NCT05316701 2026-03-04

Orca-T

Phase 3 Active not recruiting

187 enrolled 15 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

125 enrolled 18 charts 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07429266 2026-02-24

A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Phase 3 Not yet recruiting

Polycythemia Vera

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT05456191 2026-02-06

ASC4START

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04468984 2026-01-09

TRANSFORM-2

Phase 3 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT03594149 2026-01-02

AZABAC

Phase 3 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05457556 2025-12-22

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Phase 3 Active not recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT03808805 2025-12-03

APHYPAP

Phase 3 Completed

Myeloproliferative Disorders

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT03268954 2025-10-29

PANTHER

Phase 3 Completed

454 enrolled 41 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02201459 2025-10-02

PETALs

Phase 3 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04285086 2025-08-13

SURPASS ET

Phase 3 Active not recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential

NCT05481151 2025-08-13

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Phase 3 Active not recruiting

Polycythemia, Polycythemia Vera, Thrombocythemia, Essential

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT05210790 2025-08-07

VERIFY

Phase 3 Active not recruiting

Polycythemia Vera

NCT06033586 2025-08-06

THRIVE

Phase 3 Active not recruiting

Polycythemia Vera

NCT02521493 2025-08-01

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Phase 3 Active not recruiting

280 enrolled 13 charts

MyeloidOther hematologic neoplasm

Down Syndrome, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04717414 2025-07-10

INDEPENDENCE

Phase 3 Active not recruiting

Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT06423911 2025-06-03

POLARIS-2

Phase 3 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05413915 2025-05-21

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06927232 2025-04-15

AZA+Lus VS AZA Monotherapy in HR-MDS

Phase 3 Not yet recruiting

Higher-risk Myelodysplastic Syndrome

NCT03106779 2025-04-08

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Phase 3 Completed

233 enrolled 10 charts 2 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03016130 2025-04-07

UF-BMT-LDND-101

Phase 3 Terminated

MyeloidOther hematologic neoplasm

Infections, Leukemia, Myelodysplastic Syndromes

NCT05883956 2025-03-20

PREFER-HMA

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT03746054 2025-03-17

PALERMO

Phase 3 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05991908 2025-02-18

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Phase 3 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05674539 2025-02-10

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Phase 3 Enrolling by invitation

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06740916 2024-12-27

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

Phase 3 Recruiting

Myeloproliferative Disorders

NCT03755518 2024-12-12

FREEDOM

Phase 3 Terminated

38 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04116502 2024-11-18

MITHRIDATE

Phase 3 Recruiting

Polycythemia Vera

NCT04655092 2024-11-08

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Phase 3 Recruiting

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

Phase 3 Completed

Myeloproliferative Disorders, Polycythemia Vera